Skip to main content

Table 2 Response to DC vaccination and results of immune monitoring

From: Combination therapy of renal cell carcinoma or breast cancer patients with dendritic cell vaccine and IL-2: results from a phase I/II trial

Pt. # DC dose Total No.
vaccines
Response Adverse effects Proliferation assay NK activity IFN-r ELISPOT CD4+25+cell proportion
R-M-1 5 × 107 2 PD No ↑↑ -
R-G-2 5 × 107 2 SD No ↑↑
R-K-3 5 × 107 3 PD No - -
R-H-4 5 × 107 2 PD No - - -
R-N-5 5 × 107 2 PD No - - -
R-L-6 5 × 107 2 PD No - - -
B-S-1 5 × 107 2 PD No
B-H-2 5 × 107 2 PD No -
B-L-3 5 × 107 2 PD No -
B-Y-4 5 × 107 2 PD No - - -
  1. ↑↑: Highly significant (p < 0.001) increased ↑: Significant (p < 0.05) increased
  2. ↓: Significant (p < 0.05) decreased -: No significant change